Rate Video

EHA 2015 | ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma

Jesús San Miguel • 11 Jun 2015

EHA 2015

Multiple Myeloma Bortezomib Carfilzomib Dexamethasone

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicenter, open-label, randomized, phase 3 ENDEAVOR trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed multiple myeloma.

The FORTE trial: the value of sustained MRD negativity

Jesús San Miguel • 16 Dec 2020

MM early intervention & cure

Jesús San Miguel • 15 Sep 2019

MRD evaluation: how, when and for which goal?

Jesús San Miguel • 13 May 2022

Managing patients with high-risk myeloma

Jesús San Miguel • 22 Jun 2020

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM